CFDE Data Portal | Search LINC01231

	Label	Description
	LINC01231 Gene (Entity type)	ENSG00000236511 - long intergenic non-protein coding RNA 1231
	GSE173483 nutlin-3 U2OS 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE203329 HCC knockout 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 12 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 dasatinib 8 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE103567 EZH2 inhibition 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 dasatinib 8 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 2 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Prostate 20-29 vs 40-49 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Prostate 20-29 vs 30-39 Up Gene Set (Entity type)	A Gene Set from GTEx

LINC01231

ENSG00000236511 - long intergenic non-protein coding RNA 1231

GSE173483 nutlin-3 U2OS 1 v 0 human dn

A Gene Set from LINCS

GSE203329 HCC knockout 2 v 1 human dn

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 12 v 8 human dn

A Gene Set from LINCS

GSE135514 dasatinib 8 v 9 human up

A Gene Set from LINCS

GSE103567 EZH2 inhibition 5 v 2 human up

A Gene Set from LINCS

GSE135514 dasatinib 8 v 6 human up

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 2 v 6 human up

A Gene Set from LINCS

GTEx Prostate 20-29 vs 40-49 Up

A Gene Set from GTEx

GTEx Prostate 20-29 vs 30-39 Up

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.